Press Releases Year All20242023202220212020201920182017201620152014 Coherus Completes Divestiture of Ophthalmology Franchise Mar 04, 2024 Coherus BioSciences Announces New Employment Inducement Grants Feb 23, 2024 Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 21, 2024 Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP Feb 05, 2024 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Jan 22, 2024 Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium Jan 18, 2024 INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) Jan 04, 2024 Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference Jan 03, 2024 Coherus Announces U.S. Launch of LOQTORZI™ Jan 02, 2024
Year All20242023202220212020201920182017201620152014 Coherus Completes Divestiture of Ophthalmology Franchise Mar 04, 2024 Coherus BioSciences Announces New Employment Inducement Grants Feb 23, 2024 Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 21, 2024 Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP Feb 05, 2024 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Jan 22, 2024 Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium Jan 18, 2024 INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) Jan 04, 2024 Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference Jan 03, 2024 Coherus Announces U.S. Launch of LOQTORZI™ Jan 02, 2024
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 21, 2024
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Jan 22, 2024
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium Jan 18, 2024
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) Jan 04, 2024
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference Jan 03, 2024
